Ladies and gentlemen, welcome to the Dexcom third quarter 2025 earnings release conference call. My name is Abby, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. During the question-and-answer session, if you have a question, please press star one on your Touchtone phone. As a reminder, the conference is being recorded. I will now turn the call over to Sean Christensen, Vice President of Finance and Investor Relations. You may begin. Thank you, Operator, and welcome to Dexcom's third quarter 2025 earnings call. Our agenda begins with Jake Leach, Dexcom's President and Interim CEO, who will summarize our recent highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jereme Sylvain, our Chief Financial Officer. Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts to limit themselves to one question each so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our third quarter 2025 performance on the Dexcom Investor Relations website on the Events and Presentations page. With that, let's review our Safe Harbor statement. Some of the statements we will make on today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans, and performance. All forward-looking statements included on this call are made as of the date hereof based on information currently available to Dexcom, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in Dexcom's annual report on Form 10-K, most recent quarterly report on Form 10-Q, and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this call or to conform these forward-looking statements to actual results. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP. Unless otherwise noted, all references to financial measures on this call are presented on a non-GAAP basis. This non-GAAP information should not be considered in isolation or as a substitute for results or superior to results prepared in accordance with GAAP. Please refer to the tables in our earnings release and the slides accompanying our third quarter earnings call for a reconciliation of these measures to their most directly comparable GAAP financial measure. Now, I will turn it over to Jake. Thank you, Sean, and thank you, everyone, for joining us. Before we begin, I'd like to take a moment to recognize Kevin Sayer, who's not on the call today and, as many of you know, has taken a temporary medical leave. Kevin, I know you're listening today, and I look forward to catching up with you after the call. Now, on to the quarter. Today, we reported third quarter organic revenue growth of 20% compared to the third quarter of 2024. We continue to benefit from category growth, recent CGM access expansion, and solid share performance in both our U.S. and international businesses. In the U.S., we again saw more of our new customer starts coming from the entire Type 2 population as we benefited from the growing Type 2 coverage and expanded reach within primary care. As a reminder, we now have coverage established for anyone with diabetes with the national formularies of three of the largest commercial pharmacy benefit managers. This includes active coverage for nearly 6 million Type 2 non-insulin lives, which represents about half of the Type 2 NIT commercial population in the U.S. Of course, the journey is not done, and we will continue to work tirelessly until we have coverage for this entire population of more than 25 million Americans. What continues to give us confidence is the growing body of CGM outcomes evidence for this population. This leads us to believe that this access expansion is a matter of when, not if. Given the significant level of CGM usage that already exists among this cohort, we have more real-world evidence available today than we have ever had in any of our prior advocacy campaigns. We also already have seen positive updates to the latest standards of care for this group, which we expect to be further strengthened as randomized control trial data continues to emerge. This summer, we saw the first wave of non-insulin RCT outcomes presented at the annual ADA Conference, and we are now working to build on that with our own well-designed RCT. We built our trial to be representative of the wide spectrum of people with Type 2 diabetes and look forward to providing a readout early next year. Similar to our mobile and diamond studies, we believe this data set can become the cornerstone of our ongoing Type 2 evidence roadmap. This not only helps us advocate for the remaining Type 2 lives in the U.S., but it also helps us as we push for greater Type 2 coverage across the globe. As our customer base becomes increasingly diversified with this broader coverage, we have also continued to iterate our product experience to make it more personalized for each of our users. One example that I'm particularly excited about is a new feature called Dexcom Smart Basal. As we continue to learn more about the Type 2 customers on basal insulin and their healthcare providers, we've observed several trends. First, there's apprehension to start basal insulin for those who truly need it. More than one in three patients avoid basal insulin altogether because of the fear of hypoglycemia. For those who are on basal insulin, about half of the customers who ultimately progress to mealtime insulin never reach an optimal dose of basal insulin. For those that do, it typically takes several months to find the right dose. We have an opportunity to make this experience so much better for our customers. Dexcom Smart Basal is a titration module built within the Dexcom app that is designed to make basal insulin titration and management simpler, faster, and personalized for our customers. Our algorithm team designed this new software to learn from the daily glucose patterns of customers and better identify the ideal timing and dose of their basal insulin. With Smart Basal, we also expect to improve adherence and greatly reduce the required workflow for the prescribing community, as titration has historically required ongoing manual inputs and frequent office visits. Dexcom Smart Basal is currently under review with the FDA and for CE Mark. Once available, this feature will further advance our value proposition amongst the Type 2 basal population and for the physicians that treat them. We also continue to enhance the value proposition of Stelo with ongoing software updates, broader distribution, and new metabolic health partners. I'm very proud of how far Stelo has come in such a short period of time. In just the first 12 months on the market, Stelo has surpassed $100 million in revenue and has increased awareness of what CGM can do for everyone to improve metabolic health. We are continuously making the app more personalized and engaging. We've simplified ordering and reordering, and our growing base of partners has enabled broader health insights for our customers. This is just the beginning. We'll continue to make this feel like more of a consumer experience over time. We've also been getting a lot of inbound interest recently in bringing Stelo to the international market and look forward to these extensions in relatively short order. In addition, everyone at Dexcom is very excited for the broader launch of our G7 15 Day system. Over the past few months, our team has done an incredible job securing reimbursement for this product at the same net price to Dexcom and low out-of-pocket costs for our customers. In fact, we now have contracts finalized with Medicare, every major commercial payer, and our commercial DME partners. By finalizing these contracts, we've cleared a key step to enable our broad-based launch. As we've previously mentioned, we're currently in our initial launch with our warrior community as we gather feedback for our broader launch. We are looking forward to our broader rollout in the coming weeks. As we expand this launch, we are also continuing to innovate on the entire customer service experience. We recently introduced a completely new digital experience called My Dexcom Account, which is rolling out country by country as we speak. My Dexcom Account is a new online account portal that streamlines and simplifies the Dexcom digital experience. Built on direct customer feedback, this new platform will allow instant connectivity for online support, real-time visibility into orders or open tickets, and active tracking for sensors. It will also greatly simplify service requests for our customers as the site can autofill necessary user information, including the serial number of a sensor that may require service. Between updates like this, our new pharmacy replacement model, ongoing software investment, and our continued focus on product performance, we are demonstrating our commitment to advancing the customer experience. This is just as true today, despite some of the media that has been circulating on this topic. Let me make one thing clear. The customer is and will always be the North Star for this company. This is what drives us every single day, and it's what's also driven me here at Dexcom for over 20 years. That will not change. I recognize the investment community is attempting to interpret data on this topic. As we recently shared, our complaint rates for G7 have been largely stable over the past couple of years, and this continues to be the case across important categories, including sensor performance. I also want to speak to our loyal customers and prescribing community today. If any of you have an experience with Dexcom that does not meet your expectations, we understand, and that is not good enough for us. We're always listening, and we're always making improvements as a result. For G7, this has included improvements in Bluetooth connectivity, improvements to the adhesive, and most recently, addressing deployment challenges that we identified earlier this year. Through this ongoing work, our product continues to get better. Status quo has not and will never be our guiding light. I'm confident to say that the quality of the sensors coming off our lines today is exceptional and meets our high standards and the expectations of our customers. To close, I just want to note that I am honored and excited to be serving as Dexcom's next CEO. During the fall conference circuit, I had the opportunity to lay out my initial vision as the next CEO and share my conviction in this business over the long term. I look forward to sharing even more over the coming months. Our future remains very bright. Our team is incredibly strong, and the opportunity ahead of us to transform metabolic health is unlike that at any company I can think of. With that, I'll turn it over to Jereme for a financial update. Thank you, Jake. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release as well as the slide deck on our IR website. For the third quarter of 2025, we reported worldwide revenue of $1.21 billion, compared to $994 million for the third quarter of 2024, representing growth of 22% on a reported basis and 20% on an organic basis. As a reminder, our definition of organic revenue excludes the impact of foreign exchange in addition to non-CGM revenue acquired or divested in the trailing 12 months. U.S. revenue totaled $852 million for the third quarter, compared to $702 million in the third quarter of 2024, representing an increase of 21%. As Jake mentioned, we continue to see all areas of Type 2 diabetes become a bigger contributor to our U.S. new starts given our broader presence within primary care, significant new coverage within the non-insulin market, and the continued growth of the basal market. We will work to further build on this momentum, particularly as we push for even broader coverage for this group. International revenue grew 22%, totaling $357.4 million in the third quarter. International organic revenue growth was 18% for the third quarter. This marked our third straight quarter of accelerating growth internationally, with particular strength coming from regions where we have expanded access in recent quarters. For example, France continues to stand out as one of our fastest-growing markets year to date. In fact, our growth in France has accelerated during every quarter of 2025 as we have built off the significant new coverage that we finalized late last year. Canada also performed very well during Q3 as we saw a nice uptick in demand follow quickly behind our new coverage in Ontario. As a reminder, in both of these markets, we now have coverage secured through basal insulin use, and we expect more markets to move this way over time. These are great examples of the type of growth we can deliver as this Type 2 coverage emerges. Our third quarter gross profit was $741.3 million, or 61.3% of revenue, compared to 63.0% of revenue in the third quarter of 2024. During the third quarter, we made continued progress in stabilizing our global sensor supply as we were able to fully restock our level of educational samples in the field and further rebuild our finished goods inventory levels internally. Given this progress, we were able to taper back our investment in expedited shipping by the end of Q3. In fact, we recently began shipping via ocean freight once again, beginning the transition back to more cost-efficient methods of transportation as we close 2025. While these supply dynamics have progressed in line with our plan, our third quarter gross margin was impacted by scrap rates at our manufacturing facilities that were higher than expected, albeit an improvement from the second quarter. As Jake mentioned, earlier this year, our team identified certain third-party components that were contributing to an uptick in deployment issues for our sensors. While we have since addressed that issue directly, we have chosen to provide extra scrutiny to supplied products to ensure the highest quality product gets into the field, even if this results in higher costs in the near term. We expect these scrap rates to continue to improve in the coming months. Operating expenses were $468.4 million for Q3 of 2025, compared to $413.9 million in Q3 of 2024. Despite some of the challenges on gross margin, the company has been incredibly focused on managing operating expenses, even as we increase our investment in R&D spend. Operating income was $272.9 million, or 22.6% of revenue in the third quarter of 2025, compared to $212.0 million, or 21.3% of revenue in the same quarter of 2024. Adjusted EBITDA was $368.4 million, or 30.5% of revenue for the third quarter, compared to $300.1 million, or 30.2% of revenue for the third quarter of 2024. Net income for the third quarter was $242.5 million, or $0.61 per share. This was the highest quarterly earnings per share in the history of our company. We remained in great financial position, closing the quarter with greater than $3.3 billion of cash and cash equivalents. We had a very strong free cash flow quarter, which helped us increase our cash and cash equivalents balance by nearly $400 million, even as we repurchased shares over the course of the quarter. This cash level provides us with significant flexibility, and given where our shares are currently priced, we plan to settle our upcoming $1.2 billion of convertible notes in cash. In addition, we plan to remain in the market this quarter, repurchasing additional shares. Even after settlement of this convert, we'll have plenty of cash on hand to assess ongoing capital allocation opportunities, including additional repurchases. Turning to guidance, we are raising our revenue guidance to a range of $4.630 billion- $4.650 billion, representing growth of approximately 15% for the year. For margins, we are lowering our 2025 non-GAAP gross profit margin guidance to approximately 61% to reflect the additional scrap dynamics we discussed earlier. For both non-GAAP operating margin and adjusted EBITDA margin, we are now guiding to a range of 20%- 21% and 29%- 30%, respectively, as we expect to offset some of the gross margin pressure through continued OPEX leverage. With that, we can open up the call for Q&A. Sean? Thank you, Jereme. As a reminder, we ask our audience to limit themselves to only one question at this time and then re-enter the queue if necessary. Operator, please provide the Q&A instructions. Thank you. We'll now begin the question-and-answer session. If you have a question, please press star one on your Touchtone phone. If you wish to be removed from the queue, press star one a second time. If you are using a speakerphone, you may need to pick up the handset first before pressing the numbers. Once again, if you have a question, please press star one on your Touchtone phone. Our first question comes from the line of Travis Steed with Bank of America. Your line is open. Hey, everybody. First, I wanted to send well wishes to Kevin. Hope things are going well. I look forward to having you back. The question is, there's been a lot of attention on Street 2026 estimates and what your growth might look like in 2026. I'm just curious if there's any color you could share with us today as we start to think about our 2026 growth and the modeling at a high level. Yeah. Thanks, Travis. You know, while we're not going to provide specific guidance for 2026, I'm happy to give you a little color on how we think about framing up our guide for 2026. The way we look at it as we're building it up for the year, when you start the year, there's a lot of different variables that can play out throughout the course of operating throughout the year, a lot of puts and takes. We obviously, that's why we often frame it based on a range. When I think about the current coverage landscape that exists today globally, those that today have coverage and access to CGM, it certainly unlocks and affords a nice runway of growth for the next couple of years, certainly in that double-digit range. I think as we look at our range, the top end of our range is probably slightly below where the Street is today for our base case. Certainly, there are opportunities for us to outperform should they happen, things like expanded access and our ability to take share based on our innovation pipeline. From a base case perspective, we really think that the top end of that range probably comes in just under where the Street is. Our next question comes from the line of Larry Biegelsen with Wells Fargo. Your line is open. Hi, Jake. Hi, Jereme. This is Simran on for Larry. Thanks for taking the questions here. I just wanted to maybe start off with the commentary around G7 and G7 performance and the noise during the quarter. It sounds like those issues have been resolved from an engineering standpoint or a manufacturing standpoint. Can you just please confirm that? Has the noise been disruptive to new starts or prescribing patterns in Q3 at all? Do you expect it to be disruptive in Q4 or 2026? Yeah. Thanks, Simran, for the question. As I mentioned, we feel really good about the quality of the sensors that we're producing, both from accuracy, reliability, and also addressing those deployment challenges that we ran into at the beginning of the year. Our teams learned a tremendous amount about those and have been able to really solve them in the factory. We're feeling great about the product. I've actually been out in the field recently talking to customers, spending quite a bit of time with both prescribers and those using our products, really listening and making sure that we're addressing all their concerns and understanding what they're experiencing. I am hearing from all of them that things have improved since those deployment challenges we experienced in the front half of the year. We feel really good about where we're headed. Yeah. To your question on potential impact on patients in the field, around the fringes, we have heard questions out there. Those are things we're out addressing, as Jake mentioned, getting out into the field and making sure folks understand what happened. The reality is, we see that the complaint rates, while they're consistent with where they've been in the past. We know those types of complaints are the frustrating ones. There's likely been a bit of an impact on new starts here over the course of the third quarter. The good news is, we're still hundreds of thousands of new customer starts in the U.S. and certainly strong outside the U.S. as well. While the quarter was impacted by it's slightly below a record, still really strong performance over the course of this quarter. Really proud of that. I'm really excited about what happens now as we've addressed any of these concerns out there. We're really excited to see how this impact, along with our sales force, along with some of the educational samples that are available, along with supply being in a good position, how it'll impact us here in the fourth quarter and beyond. Our next question comes from the line of Robbie Marcus with JPMorgan. Your line is open. Oh, great. Thanks for taking the question. I wanted to ask, as you look at the new patients, where are you seeing the most growth? Is it kind of slowing down in Type 1 and Type 2 intensive, and getting most from basal and non-intensive? Do you need to do anything differently out in the market, whether it's advertising or the field force, to keep driving uptake of these increasingly new and important patient groups? Thanks a lot. Sure, Robbie. Yeah, this is Jereme. I can answer that. I think where we see the growth, we still see strong performance really across all the Type 2 markets. That includes intensive as well. We've seen a lot of new patients coming in, Type 2 intensive, basal, and certainly a non-insulin as coverage is out there. We still see a decent amount of Type 1 patients, but of course, as you know, Type 1 is most penetrated and smallest population. Naturally, as we get bigger and more coverage, you're going to see that. To your question then, how do we go to market and where do we go? You're 100% right. I mean, our teams are constantly looking at where we call, who we call on, which channels we market in, and where folks go. We do think about it a little bit differently. I often compare it to shaking a tree, right? Sometimes you shake a tree, you got to move to the next tree to shake it. We are doing those kinds of things as we look at where the opportunities are. Well taken. Something I know the internal team has been looking at and will continue to look at is making sure that we continue to drive the growth and find the patients. I mean, when you look at how much coverage is out there, there are many more people with coverage than there are people that are already using CGM. There's a lot of opportunity out there to go get. Our next question comes from the line of Danielle Antalffy with UBS. Your line is open. Hey, good afternoon, guys. Thanks so much for taking the question. Jake, I just wanted to follow up on Travis's question, and thanks for the color you gave and the framing. I guess I just want to clarify one point, that is, it sounds like that is assuming no expanded coverage. What are your latest thoughts on potential for expanded coverage in 2026? I guess the bigger question is, will you guide according to your thoughts on expanded coverage, or will you only reflect guidance based on coverage today? I'll leave it at that. Thanks. Yeah. Thanks, Danielle. To be clear, when we think about a base case for next year's guide, it includes the coverage that we have today, what the landscape looks like, both across insulin use and non-insulin use, and as we look globally. That's really how we're going to think about our base case guide for the year. Yeah. As we move through the course of the year, we'll make sure we point out the wins that are significant, right? There's always little wins here and there, but the wins that are significant. You know, Danielle, you know there's some potential big wins out there, both across non-insulin, basal, and even really, even as you get into some more emerging markets. There's a lot of opportunities for wins, but again, our base case won't include those. Our next question comes from the line of Matt Taylor with Jefferies. Your line is open. Hi, thank you for taking the question. I guess I'll stay on this thread for a minute. You've gotten the 6 million commercial lives covered. I think based on mobile and prior analogies, we might expect it would be natural to see you have that readout, submit it, and get NIT2 coverage by the end of next year, around that timeframe. There's been some chatter that maybe that comes earlier. I don't know exactly where that's coming from. Could you talk about the potential to get broader NIT2 coverage earlier in 2026, and what would be the mechanism to do that? Yeah. Thanks, Matt. I think, as I mentioned before, this is really our expectation. It's, you know, it's not if, it's just when. This coverage is going to come. The benefits for users are so clear in this population of non-insulin users. As we continue to see further expansion, whether you look at it from a, you know, the cost savings perspective to a payer in the first year, or you really look at those outcome results that patients get. One of the things I think about is the study that we did in primary care, in a very focused area in Ohio, where when we started that trial, the patients, there was over 170 patients in that study. Only one of them was meeting the ADA's recommended guidelines around A1C. Within a 12-month period, more than half of that group was hitting the recommended target. That was all based on CGM use. This is, again, not a non-insulin population. Just that type of powerful outcome is clearly some of the things that's powering this expanded coverage over time. Timing's hard to predict, but we're going to be ready for it when that coverage comes. Our next question comes from the line of Joanne Wuensch with Citibank. Your line is open. Good afternoon. Thank you for taking the question. Kevin, I hope you feel well soon. My question has to do with the 15 Day sensor. It sounds like it's in limited launch right now with the warriors, and then it'll expand. What does it take to expand into a broader group, and how do we think about the revenue contribution as well as the operating margin or gross margin potential? Thank you. Yeah. Thanks for that question. We are incredibly excited about this product launch, and it is in the warrior community today. We've got a number of folks on the sensors, and we're getting great feedback both about the performance of the sensors as well as the new extended duration and the accuracy of the product. We plan to be shipping with our channel partners here in the next couple of weeks to really begin that broader launch. A lot of getting ready for that was around making sure we got the coverage, as I mentioned, making sure we're working with our insulin partners on the integrations, and really just doing all the training and everything necessary to make this a very successful introduction of our next innovation. Yeah. To your question on the margin impacts, given the timing of the rollout, we've never really expected it to be a big contributor this year. It'll have a pretty nominal contribution from a gross margin perspective and from a revenue perspective. We do expect next year it becomes an opportunity to go after additional patients for those folks that certainly are looking for longer wear time. I think it's a great opportunity there. Clearly, from a margin perspective, all of the things we've historically said around the 15 Day product, that still all rings true. I think as that rolls out, we'll be pushing it out into the field, and we'll give you updates over the course of 2026 based on how that rollout is taking place. We sit here in a great position to launch it because our coverage is going to be robust when we launch it. Obviously, we're going to have partners that are going to be ready to catch it and handle it and integrate it. Having both of those ready, I think, is going to provide for a really exciting 2026. Our next question comes from the line of David Roman with Goldman Sachs. Your line is open. Thank you. Good afternoon, everyone. I appreciate the feedback and updates regarding the performance of G7 and what you're seeing in your own data. Can you maybe go into a little bit more detail about some of the actions you're going to undertake to ensure that that message is clear within the broader community? One of the just highlights that comes to mind here is the extent to which there is such a consumer element to this category versus some of the other segments that all of us follow. You have a much broader swath of stakeholders to target. Maybe just touch us on what the plan is to make sure that the message is consistent across all relevant stakeholders and maybe what investments you're making to enable that. Yeah. Thanks for the question, David. We are out in the field. That's one of our primary communication points with customers, both the prescribers and our users. We're out there making sure they understand all the things we've done to address this issue. One of the things I'd like to introduce is the fact that we mentioned that our complaint rates have been generally stable over time, and that is true. One of the things we did see though is at the beginning of the year, we saw those complaints around out-of-box failures increase. What was really good to see is that those increases in rates there were offset by decreases in accuracy complaints, Bluetooth complaints, a lot of things over time that we've been working on. As we fixed the issue with the deployment, we really do anticipate seeing those complaint rates come down overall, which has really been our goal for a while. When it comes to engagement with consumers, we're really looking at how do we make sure that the message is clear on exactly what performance looks like and how much we've done to improve things. That's really the message that I'm carrying, as well as our entire sales team and all of our team members here are really focused on interacting directly with our customers. Our next question comes from the line of Marie Thibault with BTIG. Your line is open. Hi, good evening. Thanks for taking the questions. Just wanted to go back to the scrap rate issue, make sure I understand that better. It sounds like that had to do with materials around deployment. Is that to do with the inserter specifically? As we think about it improving, is that something we can put in the rearview going into 2026, going into the 15 Day rollout? What's kind of the timing on putting that all behind us? Yeah. The way you think about it is exactly that. It's how the needle ultimately, you know, drops the sensor off into the skin. I think you can expect to see that really playing out. We're expecting some of that to dissipate here into Q4. When you look at the underlying standard performance and the standard costs and margin, that's been really, really solid year over year. In fact, what you would see is you'd be really pleased with what that looks like. What you're seeing is, and what's playing through in the results, is a few hundred basis points of what's played out in the combination of freight and some of the scrapping we're doing around these deployments. I would expect to see as we move into 2026, and as Jake alluded to, we're really putting this behind us, we'd expect a lot of that to dissipate. That gets you back to more of where we expected to be, a more normalized margin rate. Then you have the contributions, of course, with 15 days. We do expect to be in a good position as we exit this year and get into next year. With some of the things Jake had alluded to with lower warranty rates around Bluetooth, complaints around either accuracy and/or adhesives, as these get to be fixed as well, I think that's also a potential opportunity. Some work to be done here, but I think we're putting it behind us. Obviously, we see we've improved a little bit from Q2. We expect to improve again in Q4. You can see that implied by our guidance, which puts us in a good spot as we move into 2026. We'll give you a little more clarity when we give official guidance for 2026 here in the next few months. Our next question comes from the line of Matthew O'Brien with Piper Sandler. Your line is open. Good afternoon. Thanks for taking the question. I hope Kevin is recovering right now, but just wanted to talk about the guidance for Q4. On a two-year stack basis, we've decelerated here in Q3, especially domestically. I think Q4 is also implying another step down on a two-year stack basis. I think most of that's probably domestic based on how well you're doing internationally. Why is that decelerating? If you do the two-year stack in Q4, it's a little less than 10% growth. Why are we comfortable in low double digits in 2026 if you've got some deceleration here at the end of 2024? Sorry, end of 2025. Thank you. Sure. Let me maybe talk about the quarter and just, especially maybe more importantly, the guidance. I think that's what you're getting at is exit rates. We understand where we're getting at. I'd first and foremost say, when you look at the year over time, the one thing to be mindful of is we're starting to see a more normalization in the seasonality of our business. I think first you have to remember, and that's been happening over years now, and as you go back, you'll see it, where the contribution as a percentage of the full year has been declining in Q4, and the contribution from Q1 has been increasing. I would expect that to continue to take place this year. As you're comparing it, the one thing to be thoughtful about is Q1 actually has now a seasonality benefit. You saw it this year, quite frankly. I think you expect to look at it from that perspective. When you peel that back, actually what you're seeing is a pretty solid stack growth rate. When you peel back those, remember, that Q4 dynamic now has been happening now for multiple years. I think it's important that as you zoom out and you think of it from that perspective, you look at the underlying patient base, which I think your models will show the underlying user growth has been solid. I think what you're also expecting to see is the delta between unit volume growth and revenue start to come closer. You're seeing it here in the third quarter, and you're going to see it here for the back half of the year. You put all those together, solid underlying user growth, which is how we really measure the business, and that continues to go well with consistent pricing and then the seasonality effect. In effect, I think you can start to see exactly how we're thinking about next year. That's just as a base case. Hopefully that gives you some context. Always happy to talk further about it, but I would include those as you're assessing kind of modeling seasonality. Our next question comes from the line of Michael Polark with Wolfe Research. Your line is open. Thank you. Good afternoon. I wanted to ask on gross margin and the fourth quarter implied guide, which were the last two questions. I guess I'll follow up on the gross margin, Jereme. I heard a few hundred basis points cumulatively from scrap and freight. Can you spike out or remind us on just how much is the freight component, how much is the scrap component, as we run that out through the rest of the year? Thank you. Or into 2026. Yeah, it's basically 50/50. It's in that ballpark of the impact. If you remember, we had in Q1, we had to expedite some freight, and then we talked about for the rest of the year being about 75 basis points for the rest of the year on the full year numbers, by the way. You can see why on the full year, when you put it all together, it's about 50/50. Now, as we get back to more ocean freight, and we expect to do that here, obviously, we've put some stuff on ocean here exiting the third quarter and into the fourth quarter. Next year, the goal is to have a majority, if not all, of our product really moving via ocean, especially as it comes over from Malaysia. I'd expect to see certainly some benefit there. As Jake alluded to, the out-of-box failures through the work we're doing around sensor deployment, as that comes down, we expect to see that dissipate. Think about 50/50 on both of those, and you can think about that on this year. It gives you your jumping point exiting off of 2025 as to how to think about 2026. Our next question comes from the line of Jayson Bedford with Raymond James. Your line is open. Hi, good afternoon. Maybe just for me on the Type 2 uptake, can you just comment on the utilization within this user base versus those Type 1 users? Yeah. Thanks, Jason. When we think about the customer utilization of our system across different customers, obviously, AID customers will have the highest utilization, greater than 90% or so. Really, because of the fact that they need those sensors to power their system, they're high utilization in that group. As you kind of step down into the intensive insulin users, you're not on AID, you're still in that, you know, north 85% utilization for that group, again, because of all the benefits of the CGM and the fact that they're on intensive insulin. I want to make sure they don't have the issues with hypoglycemia or anything. If we start to take a look at the broader Type 2, starting with basal, you know, that group historically has been pretty strong on utilization, you know, between like 80%- 85%, so pretty close to those IIT users. That, again, really comes from the benefit, shows the benefit they're getting from the product. We saw that in our mobile study. We asked patients after they participated in that study, do you want to continue using CGM, and 95% of them said yes. We saw high utilization rates during that study. That's what we see in our field data. As we step down into the non-insulin Type 2, it's lower than the previous categories, but still, you know, around that 75% utilization mark. Something that we're seeing also in our Stelo product is we have quite a few Type 2 non-insulin users there that don't yet have coverage for CGM. They're using Stelo, and that's definitely the highest utilization group for our Stelo product. Our next question comes from the line of Shagun Singh with RBC Capital Markets. Your line is open. Great. Thank you so much. I was just wondering to what extent are the quality issues impacting new patient starts or dead in Q3? When do you expect to return to record levels, and do you need that expanded access to return to record levels again? Yeah. I think we covered a little bit earlier, and I know you're jumping between calls. The expectation is there's a little bit of an impact here in Q3, and we've seen it. We've said basically that Q3 was still hundreds of thousands of patients, but just slightly below a record here. The expectation is certainly as we move into Q4, I mean, the internal expectations for Q4 is to push and get back to those records. Obviously, next year, and as we get into 2026, our assumption is going to be record new year for patients in 2026. That's, again, in our base case, and that's with existing coverage. I don't think we need necessarily new coverage to push into that, and that wouldn't be our expectation going into it. Obviously, more coverage provides more opportunity. Those would be our expectations, and hopefully that gives you some context. Our next question comes from the line of Brandon Vazquez with William Blair. Your line is open. Hey everyone, thanks for taking the question. Jereme, you were talking a little bit about the gap between growth and the volume and pricing closing a little bit. I was curious if you could quantify it at all. If you do the math, kind of in the U.S. especially, where our model suggests something like $1,400- $1,500 annual revenue per patient, somewhere in that ballpark. Down a lot over the past couple of years, as you've alluded to. Where are we in the ballpark there on that pricing? How does that pricing trend over the coming years? Where do pricing declines on a year-over-year basis start to level out? Thanks. Sure. Yeah. I don't think you're far off. At the end of the day, we give patient numbers at the end of the year, and you can do the math globally, and we've talked about the various splits. I think you're in the general ballpark there. The price over the year-over-year price isn't much of an impact channel by channel, and I think that's really important to note. We don't necessarily have significant pricing impacts, say retail to retail or DME to DME year over year. Those typically fall in that 2%- 3% range. Where we typically see it is in mix. In mix, it's where you have folks moving. Typically, there's been a move to the pharmacy over time. That has been stabilizing over time. What you're seeing is you're starting to see that coming in, and you'd expect to see it come in. We talked about this at the beginning of the year. It's playing out as we expected. The interesting thing going forward is just going to be, and this is why it's not necessarily giving a number, but it's just talking through how it's going to work. As you start to think about where coverage exists today and as coverage gets knocked down, most of the new coverage opportunities are coming via the pharmacy. You think about Type 2 coverage. Type 2 coverage in NIT is coming through the pharmacy, so that's where your volume is going to continue to grow. On the flip side, there's been a lot of talk about CMS coverage for Type 2 and where that would be. A lot of that would come through our DME partners, where you have Medicare Fee for Service going, and that would then change the method over time. In both of those models, remember the price year over year isn't necessarily impact. It's where patients are getting access to their product and therefore the underlying mix that makes that up. I think what I would say is price isn't the challenge. It isn't the head. It's more mix, and the mix has really stabilized. Usually what happens is when we pick up a lot of new coverage, that's a good thing at the end of the day. Obviously, a lot of coverage in Type 2, that's a great thing. Hopefully, and I know we've talked about it a little bit here earlier on the call, we're expecting a time when there's CMS coverage over Type 2 non-insulin, and that could swing it the other way. It's just important to have your model set up that way. It'll help you follow along. Our next question comes from the line of Jon Block with Stifel. Your line is open. Great. Thanks, guys. Good afternoon. You know, the OpEx leverage has made up for some of the gross margin shortfalls throughout 2025 to help with margin expansion this year. I'm just curious, when we think about 2026, is that sort of like a pure role reversal due to 15 Day? Jereme, you mentioned the underlying GM getting better. Are there arguably additional OpEx opportunities that you still have? I guess where I'm getting at is how do we think about, you know, catch-up spend, if that's the right way to frame it, into 2026 on the OpEx line? Thanks. Yeah. What I would say is the work we've done this year is less about catch-up spend and deferral and things along those lines. It's really the work we've done is more around how do we get more efficient, leaning into tools, leverage, where do we hire folks in the world and how do we support things. How do we leverage the investments we've already made in technologies that we've made, quite frankly, years ago. I don't necessarily know that there's a lot of catch-up spend, but we have done a lot of great work around it this year. We'll give you a guide next year as we get there. I mean, we do obviously talk about opportunities for gross margin in 2026, and we expect there to be those opportunities there. In turn, I think there's an opportunity to continue to lever in OpEx over time. We'll see the pace in which we do that. I think we want to balance investment and don't want to necessarily miss out on opportunities. If there happens to be expansions in coverage next year, we want to be well-suited to take advantage of that. We'll make sure we balance the two. We know at the end of the day, our goal is to continue to deliver operating margin improvement over time. We'll make sure we balance those two in the best interest of growing the business long term, but also delivering results back to shareholders. Our next question comes from the line of Bill Plovanic with Canaccord. Your line is open. Hi, great. Thanks. Good evening and thanks for taking my questions. First off, I was wondering if you could talk just about the cadence of the new patient starts as we went through the quarter. Was it back end loaded, front end loaded to give us confidence that the fourth quarter might become a record quarter? I know you talked in general about attrition rates, but have you seen any trends in the attrition rates, especially as you dealt with some of the quality issues? Thank you for taking my questions. Yeah. I'll start with the second one first. The attrition rates have been relatively stable. It's all within the normal kind of range as we look at it. We pay a lot of attention to it. We track it really every week. We have a report out. We pay close attention. We keep a close eye on it, and they've been stable. In terms of trends over the course of the quarter, I think what we're seeing, at least I'll maybe say anecdotally, because I think it takes us a little time to get all the patient data in. I think you guys know this. It takes about 45 days to get it all in. I don't want to make any sort of statements about the back half of September. Other than I think it's very easy to take some of the anecdotal evidence. We're hearing a lot of very positive anecdotal evidence. As we speak to our sales leadership and as they kind of pulse the field, I think the sensor deployment issues, as those have waned in samples in the field and those have waned in the doctor's offices, you're seeing a lot of anecdotal positive feedback. Obviously that then typically leads to performance. It'd be too premature for me to give you a readout on September until I have all the data in the hands. That's the prudent thing to do. Anecdotally, I think we're very encouraged by what we're hearing. Jake, you've been meeting with physicians all the time. Maybe you can walk through kind of what you've been hearing out there. Yeah, certainly. We are hearing from our prescribers that they had some challenges earlier in the first half of this year, in particular around some of those deployments flowing through into both their offices and then into the customer's hands. When customers have issues, they tell their prescribers about it, and we heard from everybody. When we saw it, we jumped on it and we resolved it. It is very consistent feedback as I talk to users and prescribers that things have improved dramatically. That being said, issues can still happen, right? You can have an accuracy issue. You can have sensor fall off. All those things, that's why we're making the investment in our service platform and making sure ultimately that it is a competitive advantage for us. The digital investments that we've made are just the beginning around making it easy for customers to get exactly what they need. That's been a focus of mine, particularly over the last six months, looking at how can we improve what we're doing. We've had a lot of plans that have been in place, and I think we've got a lot more coming. It is a real area of focus for us to make sure that the experience of our users is the best possible. Our next question comes from the line of Mike Kratky with Leerink Partners. Your line is open. Hi, everyone. Thanks for taking our questions. I'd echo sending our best to Kevin. I'd like to circle back on a prior question just about the breakdown of price versus volume growth in your U.S. Q3 numbers. Our expectation is that we would probably start to see you anniversary some of the significant pricing headwinds that you've seen just coming from channel shifts. To what extent do you really see that in the third quarter? How should we think about that moving forward, both in Q4 and 2026? Yeah, you know, it's a good question. You clearly see some of it based on the growth number, right? The unit volume growth is based on a patient base. Our ultimate unit volumes don't necessarily change as much quarter to quarter. They're based on underlying patient growth. What you see is a comp delta there. That comp delta, as you know, is a channel mix and issue last year that certainly hit us that we're anniversarying this year. That's why you see the growth rate number there. Clearly what you're seeing is a narrowing based on the growth rate this year, but it's a bit artificial. It's a little bit higher than you otherwise would have seen because of the comp to last year. Nevertheless, you are seeing it. I think you can see it here playing out in the third quarter. I think you'll see it play out in the next quarter as well. Certainly the comps get a little bit different next quarter. I think that's important to be mindful of. As you step back over the course of the year and you look at the growth rate in the U.S., I think what you're going to see is underlying unit volumes and revenue performance are starting to tighten up. That's what we've talked about over the course of the year. Quarter by quarter, it can get a little lumpy just based on some of the challenges we had last year. Step back, you can see that playing out over time. To your point, we do expect to see that playing out in 2026. Our next question comes from the line of Richard Newitter with Truist Securities. Your line is open. Hi, thanks for taking the question. I was just wondering, keeping with the very preliminary 2026 commentary, can you describe what's in your base case for any kind of competitive dynamics, possibly even intensifying with Abbott coming out with, you know, a dual analytic? Would love to just kind of hear what you're factoring in there. Same kind of question, just what else are you willing to tell us about 2026 puts and takes as the base case as we're thinking about next year? Thanks. Yeah, you know, and appreciate the question. Our goal in, you know, at least talking to this was to give you guys some directional feedback as to what the base case would look like next year. Now, the base case doesn't represent, you know, what I would say is what we aspire to be over time, right? The base case is what I would say is a prudent way to start with the puts on the year. Things like, you know, assumption around competitor product, those are absolutely always considered in there. Obviously, we'll be thinking through anything from coverage, from known coverage decisions this year, which are already obviously in those base numbers. We'll consider all of that really around the world. That's why we give you some of that context. Getting into the specifics, you know, I think we got to give you the official guidance before we then get into the official specifics. That's why we're a little hesitant to start walking through each of the specifics. Obviously, we have a budget for next year. We have a long range plan, a five-year long range plan that we all have in-house here. We'll meet with the board here in December and roll that out for you guys as we get into next year. Again, I think the context was trying to make sure everybody had an idea for how we were thinking about base case. We'll get into those specifics when we officially give guidance, because then you can put math officially to the numbers. Our next question comes from the line of Josh Jennings with TD Cowen. Your line is open. Hi, good afternoon. Thanks for taking the question. I wanted to just, I know it's only been a couple of months since ADA and the 2Q call, but just any updates on the GA platform and whether or not ketone sensing has kind of moved up the priority list. Any timelines when we could learn more, or any timelines you can provide just in terms of when GA could move forward towards commercialization. Thanks so much. Yeah, GA is an incredibly important part of our product portfolio in the future and our future innovation. It is a multi-analytic platform. As we think about, you know, just in general, the cadence of innovation and what we're looking at, we're really focused on meeting broad user needs. Unmet needs across a broad base, we think about it in the type one space. We also think about it in, you know, some of the higher growth segments as well of the market, like our smart basal technology that we were talking about. That's a really important way to drive growth in that basal population and really meet those unmet needs. Certainly, multi-analytic is an important part of the future platform. As we look at GA, we're not going to get into the timelines now. One thing I wanted to let everybody know is we are planning to put together an investor event first half of next year. We're actually going to hold it at our Mesa manufacturing facility to give you guys a glimpse into our operations at our high volume manufacturing plant. That'll be a good opportunity for us to talk about things like LRP and the portfolio of products and, you know, all the things we plan to do to drive this business forward. Our next question comes from the line of Matt Miksic with Barclays. Your line is open. Hey, thanks so much. Can you hear me okay? We can hear you. Okay. Terrific, thank you. One question, I'm not sure if this has come up, but it's one of the things we hear in the community recently. Some folks holding on to G6 are going back to G6. I'm just wondering if that's a factor in sort of manufacturing efficiency or line management, and what your thoughts are on how and when you'll be able to transition off of that. One quick follow-up, if I could. For G6, we are consistently transitioning customers over to G7, and the number of G6 users is consistently coming down. We have heard of some folks going back to G6, and it's a very small number. It doesn't really move the needle much at all. We are going to continue to make sure that G7 meets the needs of all users across the whole spectrum, so no one has a reason to stick with G6. We know that, as we've seen in some of our previous upgrades between generations, when people are familiar with the technology and they're happy with what they got, they may stick with it, right? Over time, we are going to keep moving people over to G7. We haven't announced the official conclusion of G6 in the market. We will when the time is right, and we'll make sure we give people a heads up when that's going to happen. Okay. That's great. On just general product strategy, you know, the Dexcom ONE strategy overseas, I think has been successful in some geographies and kind of, you know, met the need that you had set out for that program. Generally, Dexcom, of course, has been kind of a core central line product, you know, with much of the innovation building the generations around the same central platform. I'm just wondering if at some point you're thinking about, you know, adjacencies or, you know, alternative, you know, approaches to helping patients manage diabetes or other glycemic elements of their life, but with a truly different platform, not a different version of G7 or G8. Love to get your thoughts. Thanks. Yeah, I appreciate that question. You know, really going into the thinking of broad markets and how do you address those unmet needs. Dexcom ONE+ is doing great. A lot of that growth in France that we talk about is on that platform, and it's really allowed us to compete in market segments that we weren't previously because we were focused on the G series products and the more acute end of the diabetes spectrum. Dexcom ONE+ is a super important part of our portfolio approach to serving the needs of different customers. The mobile apps and the experience are different there. Another example I kind of point to as we expand the opportunity here is Stelo, right? Stelo is a product that spans a pretty broad spectrum of users from Type 2 all the way down to pre-diabetes and then those that are looking at better understanding their metabolic health. We will be taking that product internationally next year, and we'll see it in a number of markets where we've had a pretty good request and demand for Stelo outside the U.S. We are, Smart Basal is a great example. I kind of mentioned it before, but that ability to help a prescriber and a patient really get to the right outcome safely. In the clinical study around Smart Basal, it was focused on getting people to the optimal dose as fast as possible with no hypoglycemia, and that's what we saw in that study. We're also excited about the opportunity for it to drive better adherence. Once users, you know, they're going on insulin for the very first time, they're taking an injection, they've maybe never done injections before, there's some apprehension there. When you show them how much better their diabetes control is when they've got the right dose of basal insulin, it's pretty motivating. We do expect to see some adherence improvements there and really just drive general outcomes. Focusing on outcomes for the broad population is what we're trying to do here, and we do it a number of different ways through different products and different software experiences. Our final question comes from the line of Anthony Petrone with Mizuho. Your line is open. Thanks. Best wishes to Kevin as well. Maybe one on gross margin as it relates to the G7 transition and one on just penetration. When you think about the transition to G7, how long do you think it will take to fully roll over the 10 Day to 15 Day? What does that do to gross margin once you're kind of on a 15 Day, you know, heavier user base? There is some chatter just on penetration, even competitive results. When you think about Type 2, non-insulin intensive hypo risk and basal only, you have basal only penetration at 20%- 25%. Non-insulin intensive hypo at under 5%. What do you think a reasonable penetration for those two segments is over your long range plan? Thanks. Yeah, I'll start with maybe the second, which is, you know, getting into the markets. We've always talked about basal as an example being a market that should get to about 60% penetration over time. That's kind of, you know, our crystal ball. It's been pretty darn accurate as we thought about type one historically and type two intensive. It's what we think about. Obviously, somebody taking insulin, having that sensor on there is a really nice thing. We've proven time and time again, the combination of the sensor plus insulin plus now, obviously, Dexcom Smart Basal in there, that's a huge opportunity to meet an unmet need in a growing market. We're really excited about that offering and that can help people manage it. We do expect that in the non-insulin and the type two hypo risk population, you know, it's hard to know. That's such a big, wide swath of population, especially type two. Those hypo risk folks, while they're covered, they do kind of sit typically, they're typically seen like a type two patient, right? We expect that to be, you know, 60% is obviously higher than we would, it would be a high mark there just given what we think basal is. Anything more than 5%, which is where it is, and as it goes up to 10%, 15%, 20%, you're talking about millions and millions and millions of people on the product. More to come as we go there. We know it's a lot more than today. We know that with coverage, it's going to be a lot more than today. We're really excited about that. Now, to your first question on gross margin, what can 15 Day do and how long will it take? If you look at historical patterns of how long it's taken from, you know, G5 to G6, G6 to G7, it does take a couple of years. As Jake alluded to, folks do get comfortable with technology. To get folks to change over, it does take a little bit of time. Our goal is obviously to go faster. Obviously, with a form factor very similar across 10 Day and 15 Day, I think there's an opportunity, but it does require a different script. We're going to work on it over time. We'll give you more feedback as it's getting out into the field. As we get into guidance next year, we'll give you a little more color about what our assumptions are. We'll have a little bit of time under our belt. More to come on that one. The impact obviously is significant for us as we move more and more from 10 Day to 15 Day and three sensors to two. The impact on margin can be significant, but it can also allow us to grow the business more, going into markets where, with maybe a Dexcom ONE+ product or other products where that 15 Day wear life allows us to really compete with what would be a cash pay or a lower reimbursement market. It allows both. It allows top line growth and going after more markets, and it allows opportunities to expand margin. Very excited about it. Ladies and gentlemen, that concludes our question and answer session. I will now turn the call back over to Mr. Jake Leach for closing remarks. Okay. Thank you, everyone, for joining us today. Thank you for the well-wishes to Kevin. I know he really appreciates that. I'd like to wrap up the call today by expressing my deep appreciation to all the employees of Dexcom. I'm extremely proud of this team and how we've continued to focus on serving our customers and not getting distracted. In the end, our core values are clear, and we will continue to be unrelenting in our mission to empower people to take control of health. We have a remarkable opportunity to improve the lives of millions of people around the world, and I couldn't be more excited about the future. Thanks, everybody. Ladies and gentlemen, this concludes today's call, and we thank you for your participation. You may now disconnect.